The government of Austria has introduced a national lottery to encourage people to get vaccinated against COVID-19, Reuters news agency reported on Thursday.
Around 72% of Austria's population is fully vaccinated against COVID-19, one of the lowest rates in western Europe.
Chancellor Karl Nehammer said he wanted there to be a financial reward for those who get vaccinated, adding: "We have learned from the past and we have seen that a vaccination lottery is the best possible way to set up such a system."
Members of the public, whether already vaccinated or not, would get a ticket for each shot they have -- three tickets in total for those who have had their booster shot.
Every tenth ticket would win a EUR500 gift voucher, Nehammer said, without specifying what the vouchers were for.
This comes as Austria's lower house of parliament is due to pass a bill making vaccines compulsory for all adults in Austria from 1 February 2022, with initial fines of EUR600 rising to up to EUR3,600 if the fine is challenged unsuccessfully.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results